| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/02/2005 | CN1187370C Connective tissue growth factor fragments and methods and uses thereof |
| 02/02/2005 | CN1187369C Method for producing peptide salts. their use, and pharmaceutical prepns. containing these peptide salts |
| 02/02/2005 | CN1187364C 类固醇衍生物 Steroid derivatives |
| 02/02/2005 | CN1187357C Calcarisporin B1 and extracting method and use in anti-tumor medicine |
| 02/02/2005 | CN1187352C Phenanthroline-7-one derivs. and their therapeutic uses |
| 02/02/2005 | CN1187347C Chromatographic separation method of paclitaxel and cephalomannin |
| 02/02/2005 | CN1187333C Certain substituted caprolactams, pharmaceutical compositions containing them and their use in treating tumors |
| 02/02/2005 | CN1187332C Tetrahydroisoquinoline hydroximic acid sulfamide compound, its synthesis method and its application |
| 02/02/2005 | CN1187326C Novel compounds |
| 02/02/2005 | CN1187325C Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 02/02/2005 | CN1187094C Polyol-IFN-beta conjugates |
| 02/02/2005 | CN1187086C Hybrid with interferon alpha and immunoglobulin Fc linked through non-immunogenic peptide |
| 02/02/2005 | CN1187081C Compound Chinese medicine for treating extensive cancer |
| 02/02/2005 | CN1187079C Auxiliary medicine for cancer and preparation thereof |
| 02/02/2005 | CN1187071C Liver cancer treating medicine and its preparation method |
| 02/02/2005 | CN1187068C Health-care product for preventing and curing cancer |
| 02/02/2005 | CN1187060C Extracts of shark cartilage, its preparation method and usage |
| 02/02/2005 | CN1187047C Application of difenitriazole in preparation of medicine for treating malignant tumour |
| 02/01/2005 | US6849746 Synthetic methods for polyphenols |
| 02/01/2005 | US6849743 Synthesis of clasto-lactacystin β-lactone and analogs thereof |
| 02/01/2005 | US6849739 N-heterocyclic derivatives as NOS inhibitors |
| 02/01/2005 | US6849713 Topisomerase inhibitor |
| 02/01/2005 | US6849658 Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them |
| 02/01/2005 | US6849653 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 02/01/2005 | US6849648 Phenylene alkyne matrix metalloproteinase inhibitors |
| 02/01/2005 | US6849646 Chromenone and chromanone derivatives as integrin inhibitors |
| 02/01/2005 | US6849643 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 02/01/2005 | US6849641 Azaindole tyrosine kinase inhibitors |
| 02/01/2005 | US6849639 Anticancer agents, antiinflamatory agents, osteoporosis, atherosclerosis |
| 02/01/2005 | US6849638 Phosphodiesterase enzyme 7b (pde7b) inhibitors; treating osteoporosis, osteopenia and asthma |
| 02/01/2005 | US6849637 Matrix metalloproteases (MMPs) inhibitors such as benzyl 4-benzyl-5-oxo-4H-(1,2,4)triazolo(4,3-a)quinazol-7-ylcarboxylate for inflammatory conditions such as rheumatoid arthritis or osteoarthritis, or cancer |
| 02/01/2005 | US6849631 Semicarbazides and their uses |
| 02/01/2005 | US6849628 Synthetic diastereoisomers of leucovorin; anticancer agents |
| 02/01/2005 | US6849626 Aza-amino acid derivatives (factor Xa inhibitors 15) |
| 02/01/2005 | US6849625 Use in manufacture of a medicament for use as an anti-invasive agent in containment and/or treatment of solid tumor disease |
| 02/01/2005 | US6849624 Headaches; antiarthritic agents; respiratory system disorders; psychological disorders |
| 02/01/2005 | US6849617 Administering Tissue factor pathway inhibitors for prophylaxis of thrombosis and cardiovascular disorders; anticoagulants |
| 02/01/2005 | US6849612 Oligonucleotide modulation of cell adhesion |
| 02/01/2005 | US6849607 Galectin recognized photosensitizers for photodynamic therapy |
| 02/01/2005 | US6849604 A decapeptides or polypeptides, plant extracts is derived from Vernonia amygdalina leaves as antitumor agents, anticarcinogenic agents, treating breast cancer |
| 02/01/2005 | US6849596 Regulatory/unfolding peptides of ezrin |
| 02/01/2005 | US6849593 Bifidogenic peptides |
| 02/01/2005 | US6849452 Bringing an enriched population of resting NK cells into contact with mature or triggered dendritic cells in vitro or ex vivo, under conditions allowing activation of such resting NK cells by mature or triggered cells |
| 02/01/2005 | US6849451 Hybrid cells |
| 02/01/2005 | US6849420 Isolated autophosphorylating polypeptide, possessing PI3 kinase (phosphoinositide-3 kinase) activity; use drug screening for regulators of cell motility, such as antimetastasis agents |
| 02/01/2005 | US6849270 Releasable linkage and compositions containing same |
| 02/01/2005 | CA2459622A1 Compositions and methods for restoring sensitivity to treatment with her2 antagonists |
| 02/01/2005 | CA2320448C 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines |
| 02/01/2005 | CA2094261C Polypeptide of a growth factor receptor family, application in the diagnosis and treatment of myeloproliferative diseases |
| 01/28/2005 | CA2469094A1 Methods for diagnosis and therapy of cancer and composition useful therein |
| 01/27/2005 | WO2005007889A1 Method for diagnosing colorectal cancers |
| 01/27/2005 | WO2005007849A1 Method of enhancing alkylating drug sensitivity |
| 01/27/2005 | WO2005007846A1 Method of judging senstivity of tumor cell to anticancer agent |
| 01/27/2005 | WO2005007832A2 System for external control of oncolytic virus replication |
| 01/27/2005 | WO2005007701A1 Intensified fusion protein fv-ldp-ae having angiogenesis inhibiting and antitumor activety and the use thereof |
| 01/27/2005 | WO2005007699A2 Human antibody molecules for il-13 |
| 01/27/2005 | WO2005007694A1 HER2/neu PEPTIDE AND THERAPEUTIC USE TEHREOF |
| 01/27/2005 | WO2005007653A2 Substituted tetrahydro-1h-pyrazolo[3,4-c]pyridines, compositions containing same and use |
| 01/27/2005 | WO2005007643A1 Novel acridine derivatives and use thereof as medicaments |
| 01/27/2005 | WO2005007631A1 Naphthylene derivatives as cytochrome p450 inhibitors |
| 01/27/2005 | WO2005007616A1 Diphenylamino ketone derivatives as mek inhibitors |
| 01/27/2005 | WO2005007603A2 Fluorocombretastatin and derivatives thereof |
| 01/27/2005 | WO2005007192A2 Cytoprotection through the use of hif hydroxylase inhibitors |
| 01/27/2005 | WO2005007190A1 Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| 01/27/2005 | WO2005007187A1 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| 01/27/2005 | WO2005007186A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 01/27/2005 | WO2005007182A1 Old platycodon extracts for prevention of metastasis and cancer formation |
| 01/27/2005 | WO2005007181A1 Old platycodon extracts for prevention angiogenesis |
| 01/27/2005 | WO2005007172A1 Glycoside-containing liposome |
| 01/27/2005 | WO2005007153A1 A composition of amino acid-iodine complex and methods for preparing and application |
| 01/27/2005 | WO2005007151A1 Chromatosis remedies |
| 01/27/2005 | WO2005007099A2 Pkb inhibitors as anti-tumor agents |
| 01/27/2005 | WO2005007085A2 Pyrazolo pyrimidine derivatives and methods of use thereof |
| 01/27/2005 | WO2005007079A2 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
| 01/27/2005 | WO2004104575A3 Diagnostics and therapeutics for diseases associated with x-prolyl aminopeptidase 2 (xpnpep2) |
| 01/27/2005 | WO2004092118A3 2-propylidene-19-nor-vitamin d compounds |
| 01/27/2005 | WO2004085418A3 Xanthones, thioxanthones and acridinones as dna-pk inhibitors |
| 01/27/2005 | WO2004066959A3 Organic-arsonic compounds |
| 01/27/2005 | WO2004062671A3 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells |
| 01/27/2005 | WO2003090687A3 Using heat shock proteins to increase immune response |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | US20050020837 N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| 01/27/2005 | US20050020836 For therapy of hyperproliferative disorder in a mammal |
| 01/27/2005 | US20050020656 L-histidine, D-histidine, DL-histidine, and/or salts thereof, and optionally cysteine, and/or cystine or salts; fibrosis may be of the kidney, pancreas, lung, vascular vessels, skin, bone marrow, or liver; may be given in foods or beverages |
| 01/27/2005 | US20050020647 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome |
| 01/27/2005 | US20050020635 C7 carbamoyloxy substituted taxane compositions |
| 01/27/2005 | US20050020624 Dihydroindole and tetrahydroquinoline derivatives |
| 01/27/2005 | US20050020615 Mixture of rapamycin with tertiary butanol or ethanol; anticancer agents, multiple sclerosis, rheumatic disease |
| 01/27/2005 | US20050020593 Anticancer agents |
| 01/27/2005 | US20050020583 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2005 | US20050020581 4H-quinazolinyl compounds; alkylation of a quinazoline with a 3-bromopiperidine-2,6-dione followed by alkylation with a heterocyclic alkyl compound; immunomodulators with increased solubility and chemical resistance to hydrolysis; alternatives to thalidomide treatment for autoimmune diseases |
| 01/27/2005 | US20050020570 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| 01/27/2005 | US20050020540 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
| 01/27/2005 | US20050020533 Ceramide analogs, process for their preparation and their use as antitumor agents |
| 01/27/2005 | US20050020523 Modified antisense nucleotides complementary to a section of the human haras gene |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020516 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| 01/27/2005 | US20050020512 In presence of acidic clay; coupling in presenc eof silver tetrafluoroborate ; anticancer agents |
| 01/27/2005 | US20050020505 Angiogenesis inhibitors; antitumor agents; anticancer agents; atherosclerosis; cardiovascular disorders; antiarthritic agents |